Reverse Transcriptase Inhibitors
"Reverse Transcriptase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template.
Below are MeSH descriptors whose meaning is more general than "Reverse Transcriptase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Reverse Transcriptase Inhibitors".
This graph shows the total number of publications written about "Reverse Transcriptase Inhibitors" by people in this website by year, and whether "Reverse Transcriptase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Reverse Transcriptase Inhibitors" by people in Profiles.
6-Arylthio-3-hydroxypyrimidine-2,4-diones potently inhibited HIV reverse transcriptase-associated RNase H with antiviral activity. Eur J Med Chem. 2018 Aug 05; 156:652-665.
6-Biphenylmethyl-3-hydroxypyrimidine-2,4-diones potently and selectively inhibited HIV reverse transcriptase-associated RNase H. Eur J Med Chem. 2018 Aug 05; 156:680-691.
Design, synthesis and biological evaluations of N-Hydroxy thienopyrimidine-2,4-diones as inhibitors of HIV reverse transcriptase-associated RNase H. Eur J Med Chem. 2017 Dec 01; 141:149-161.
6-Cyclohexylmethyl-3-hydroxypyrimidine-2,4-dione as an inhibitor scaffold of HIV reverase transcriptase: Impacts of the 3-OH on inhibiting RNase H and polymerase. Eur J Med Chem. 2017 Mar 10; 128:168-179.
Design, Synthesis, and Biological Evaluations of Hydroxypyridonecarboxylic Acids as Inhibitors of HIV Reverse Transcriptase Associated RNase H. J Med Chem. 2016 05 26; 59(10):5051-62.
3-Hydroxypyrimidine-2,4-diones as Selective Active Site Inhibitors of HIV Reverse Transcriptase-Associated RNase H: Design, Synthesis, and Biochemical Evaluations. J Med Chem. 2016 Mar 24; 59(6):2648-59.
Design, synthesis, biochemical, and antiviral evaluations of C6 benzyl and C6 biarylmethyl substituted 2-hydroxylisoquinoline-1,3-diones: dual inhibition against HIV reverse transcriptase-associated RNase H and polymerase with antiviral activities. J Med Chem. 2015 Jan 22; 58(2):651-64.
CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans. Eur J Clin Pharmacol. 2012 Mar; 68(3):267-71.
Head-to-head comparison of two first-line regimens and an NRTI-sparing regimen for initial therapy of HIV-1 infection: what should we start? Curr HIV/AIDS Rep. 2009 Feb; 6(1):1-2.
The importance of potency and durability in HIV patient antiretroviral therapy preferences: a telephone survey. AIDS Patient Care STDS. 2005 Dec; 19(12):794-802.